Volume 80, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Although nitazoxanide has been shown to have activity against in animal studies and against , its use in treatment of human cystic echinococcosis has not been reported. We report a case of progressive bony hydatid disease treated with nitazoxanide that showed a clinical and radiologic response. The patient had a 40-year history of hydatid disease involving the left hip. Despite prolonged courses of albendazole and praziquantel, she had progressive disease with extensive involvement of the left hemipelvis and adjacent soft tissue cysts. She was treated with nitazoxanide, 500 mg twice a day for 3 months in combination with albendazole. The clinical response was supported by imaging showing marked improvement in the soft tissue cysts, with stable disease in the bony pelvis. Although further studies are required, this case suggests that nitazoxanide may be an effective treatment option in hydatid disease, particularly in patients with progressive disease who are receiving conventional therapy.


Article metrics loading...

Loading full text...

Full text loading...



  1. Craig P, McManus D, Lightowlers M, Chabalgoity J, Garcia H, Gavidia C, Gilman R, Gonzalez A, Lorca M, Naquira C, Nieto A, Schantz P, 2007. Prevention and control of cystic echinococcosis. Lancet Infect Dis 7 : 385–394.
  2. McManus D, Zhang W, Li J, Bartley P, 2003. Echinococcosis. Lancet 362 : 1295–1304.
  3. Herrera A, Martinez A, 2003. Extraspinal bone hydatidosis. J Bone Joint Surg Am 85 : 1790–1794.
  4. Szypryt E, Morris D, Mulholland R, 1987. Combined chemotherapy and surgery for hydatid bone disease. J Bone Joint Surg Br 69 : 141–144.
  5. Walker M, Rossignol JF, Torgerson P, Hemphill A, 2004. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 54 : 609–616.
  6. Bonifacino R, Dogliani E, Craig PS, 1997. Albendazole treatment and serological follow-up in hydatid disease of bone. Int Orthop 21 : 127–132.
  7. Hemphill A, Mueller J, Esposito M, 2006. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin Pharmacother 7 : 953–964.
  8. Fox LM, Saravolatz LD, 2005. Nitazoxanide: a new thiazolide anti-parasitic agent. Clin Infect Dis 40 : 1173–1180.
  9. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF, 2008. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 77 : 56–63.
  10. Stettler M, Fink R, Walker M, Gottstein B, Geary T, Rossignol JF, Hemphill A, 2003. In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 47 : 467–474.
  11. Reuter S, Manfras B, Merkle M, Harter G, Kern P, 2006. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrob Agents Chemother 50 : 2966–2970.
  12. Stettler M, Rossignol JF, Fink R, Walker M, Gottstein B, Merli M, Theurillat R, Thorman W, Dricot E, Segers R, Hemphill A, 2004. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 34 : 615–624.

Data & Media loading...

  • Received : 11 Jun 2008
  • Accepted : 13 Aug 2008

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error